Tucows delivers on 2024 Adjusted EBITDA guidance and fourth consecutive year of revenue growth — Neutral
TCX PRNewsWire — February 13, 2025TORONTO , Feb. 13, 2025 /PRNewswire/ - Tucows Inc. (NASDAQ: TCX) (TSX: TC), a global internet services leader, today reported its unaudited financial results for the fourth quarter and full year ended December 31, 2024. All figures are in U.S. dollars.

Trade Desk's (TTD) Kokai Rollout Stumbles, Raising Questions About Prior Statements – Hagens Berman — Neutral
TTD GlobeNewsWire — February 13, 2025SAN FRANCISCO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- The Trade Desk, Inc. (NASDAQ: TTD), a prominent advertising technology firm, has aggressively promoted the "massive benefits" of its next-generation Kokai platform, suggesting robust early performance and hinting at further growth. These recent pronouncements, which included claims of "already seeing the results of Kokai performance today" and being "just getting started," now face scrutiny following the company's first revenue miss in 33 quarters. The discrepancy between the company's earlier optimism and its recent financial performance raises questions about the accuracy of information shared with investors.

NEW YORK , Feb. 13, 2025 /PRNewswire/ -- The Board of Directors of Omnicom (NYSE: OMC) declared a quarterly dividend of 70 cents per outstanding share of the corporation's common stock. The dividend is payable on April 9, 2025 to Omnicom common shareholders of record at the close of business on March 11, 2025.

TORONTO , Feb. 13, 2025 /PRNewswire/ - Tucows Inc. (NASDAQ: TCX) (TSX: TC) announced today that its Board of Directors has approved a stock buyback program to repurchase, from time to time if and as appropriate, up to $40 million of its common stock in the open market. The new $40 million buyback program will commence February 14, 2025 and will terminate on or before February 13, 2026.

Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR franchise implies modest growth acceleration compared to 2024, driven by Amvuttra's expected approval next month. Fitusiran's approval could result in meaningful annual royalties for Alnylam from partner Sanofi, enhancing long-term profitability and cash flows.

S&P 500 Gains and Losses Today: MGM Stock Surges as Macau, Digital Businesses Thrive — Positive
MGM Investopedia — February 13, 2025Major U.S. equities indexes moved higher as President Donald Trump signed an executive order instructing his administration to investigate reciprocal tariffs but stopped short of immediately imposing the taxes.

Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors — Neutral
MTNB GlobeNewsWire — February 13, 2025BEDMINSTER, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (the “Company”) today announced that the Company entered into a securities purchase agreement (the “Agreement”) with a certain group of investors (the “Investors”), pursuant to which they agreed to purchase from the Company 3,300 shares of Series C Convertible Preferred Stock (the “Preferred Stock”) and warrants to purchase up to 11,262,808 shares of common stock at a purchase price of $1,000 per share of Preferred Stock and accompanying warrants for aggregate gross proceeds of $3.3 million before deducting offering expenses payable by the Company.

CARS to Announce Fourth Quarter and Full Year 2024 Financial Results — Neutral
CARS PRNewsWire — February 13, 2025CHICAGO , Feb. 13, 2025 /PRNewswire/ -- Cars.com Inc. (NYSE: CARS) (d/b/a "Cars Commerce Inc" or the "Company"), an audience-driven technology company empowering the automotive industry, today announced that it expects to report its financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025. The Company will host a conference call with a live webcast at 8:00 a.m.

Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow — Neutral
PROF GlobeNewsWire — February 13, 2025TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025.

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages NAPCO Security Technologies, Inc. Investors to Inquire About Securities Class Action Investigation - NSSC — Neutral
NSSC Accesswire — February 13, 2025NEW YORK, NY / ACCESS Newswire / February 13, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of NAPCO Security Technologies, Inc. (NASDAQ:NSSC) resulting from allegations that NAPCO may have issued materially misleading business information to the investing public. SO WHAT: If you purchased NAPCO securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Stoneridge, Inc. To Broadcast Its Fourth Quarter 2024 Conference Call On The Web — Neutral
SRI PRNewsWire — February 13, 2025NOVI, Mich. , Feb. 13, 2025 /PRNewswire/ -- Stoneridge, Inc. (NYSE: SRI) will webcast its fourth quarter 2024 earnings conference call live on Thursday, February 27, 2025, at 9:00 a.m.

Alamos Gold Announces Development Plan for High-Return Burnt Timber and Linkwood Satellite Deposits — Neutral
AGI GlobeNewsWire — February 13, 2025Burnt Timber and Linkwood to significantly extend mine life of Lynn Lake project and enhance economics given low-capital and high after-tax Internal Rate of Return of 54%

APLT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Applied Therapeutics, Inc. Investors to Secure Counsel Before Important February 18 Deadline in Securities Class Action - APLT — Neutral
APLT Accesswire — February 13, 2025NEW YORK, NY / ACCESS Newswire / February 13, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Applied Therapeutics, Inc. (NASDAQ:APLT) between January 3, 2024 and December 2, 2024, both dates inclusive (the "Class Period"), of the important February 18, 2025 lead plaintiff deadline. SO WHAT: If you purchased Applied Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

MDU Resources Announces New Vice Chair of the Board of Directors — Neutral
MDU PRNewsWire — February 13, 2025BISMARCK, N.D. , Feb. 13, 2025 /PRNewswire/ -- MDU Resources Group Inc. (NYSE: MDU) announced today that its board of directors has elected Darrel T.

Arm (ARM 6.06%) stock posted gains in Thursday's trading. The semiconductor company's share price closed out the daily session up 6.1% amid the backdrop of a 1% increase for the S&P 500 (^GSPC 1.04%) and a 1.5% gain for the Nasdaq Composite (^IXIC 1.50%).

Ryde Hosts Annual CNY Lunch, Honoring Top Driver-Partners and Strengthening Driver Engagement — Neutral
RYDE Accesswire — February 13, 2025SINGAPORE / ACCESS Newswire / February 13, 2025 / In a move to reaffirm its commitment to driver-partners, Ryde Group Ltd (NYSE American:RYDE) ("Ryde'' or the "Company"), a technology company with a leading platform for mobility and quick commerce in Singapore, hosted its Annual CNY Lunch, celebrating the dedication of its top six driver-partners. The event, held in the spirit of appreciation and community, also reinforced Ryde's industry-leading 0% commission model, which ensures that driver-partners take home more of their well-deserved earnings - a stance that sets it apart from other ride-hailing platforms.

Grab Holdings, the "Uber of Southeast Asia," has shown significant growth in key mobility, delivery, and financial services segments, and sports a solid competitive moat. Trading at a reasonable valuation, we think that shares are still attractive, despite the recent 40%+ run up. We're re-iterating our 'Strong Buy' rating on GRAB.

Curtiss-Wright Corporation (CW) Q4 2024 Earnings Call Transcript — Neutral
CW Seeking Alpha — February 13, 2025Curtiss-Wright Corporation (NYSE:CW ) Q4 2024 Earnings Conference Call February 13, 2025 11:00 AM ET Company Participants Jim Ryan - Vice President, Investor Relations Lynn Bamford - Chair and CEO Chris Farkas - Vice President and CFO Conference Call Participants Nathan Jones - Stifel Mike Ciarmoli - Truist Securities Myles Walton - Wolfe Research Jason Gursky - Citigroup Peter Arment - Baird Pete Skibitski - Alembic Global Bryce Sandberg - William Blair Operator Welcome to the Curtiss-Wright Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode and the …

Cloudflare Q4: AI Agents & Inference Driving Up Enterprise Momentum (Downgrade) — Positive
NET Seeking Alpha — February 13, 2025Cloudflare, Inc.'s stock has outperformed the S&P 500, growing over 89% since my last publication, but future growth estimates are fully priced in, leading me to downgrade it to a “hold” with a $175 price target. The company reported a 27% YOY revenue increase and a 68% rise in non-GAAP operating income, driven by robust enterprise momentum, with the number of $500K+ and $1M+ customers growing even faster. Management is expanding sales capacity and capex to capture AI inference market share with its Worker AI platform, sacrificing short-term margins for long-term growth.

Quest Diagnostics to Host Investor Day on March 19, 2025 — Neutral
DGX PRNewsWire — February 13, 2025SECAUCUS, N.J. , Feb. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will host an Investor Day for institutional investors and financial analysts in New York City on Thursday, March 19, 2025 at the New York Stock Exchange.
